M&A / Deals RA Capital targets China with latest SPAC deal BioPharma DiveThe prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing.M&A / DealsRead full story pharminent March 24, 2026 (Last updated: March 25, 2026) BioPharma Dive The prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing. M&A / DealsRead full story Post navigation Previous: Immutrin raises $87M to advance drug for progressive heart diseaseNext: Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
